Benitec Biopharma Inc.
Business
Benitec Biopharma Inc. is a clinical-stage biotechnology company developing novel genetic medicines using its proprietary DNA-directed RNA interference (ddRNAi) and "silence and replace" platform technologies. The company's lead product candidate, BB-301, is an AAV-based gene therapy designed to permanently silence disease-causing genes while simultaneously replacing them with functional wildtype genes for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). The company is conducting clinical development activities in the United States and may pursue strategic collaborations or out-licensing arrangements for further development and commercialization of its ddRNAi-based product candidates.
Summary from 10-K filed 2025-09-22
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Royalties and license fees | 0 | −108,000 | 0 | 9,000 | 123,000 | |
| Research and development | 18 | 16 | 13 | 11 | 7 | |
| General and administrative | 23 | 7 | 6 | 7 | 7 | |
| Total operating expenses | 42 | 22 | 19 | 18 | 14 | |
| Loss from operations | −42 | −22 | −19 | −18 | −14 | |
| Foreign currency transaction gain (loss) | −71,000 | 40,000 | −415,000 | −232,000 | −333,000 | |
| Interest income (expense), net | 3 | 904,000 | −33,000 | −32,000 | −6,000 | |
| Other expense, net | −131,000 | −204,000 | −30,000 | −79,000 | 37,000 | |
| Gain on extinguishment of liabilities | 764,000 | 0 | — | — | — | |
| Unrealized loss on investment | 0 | −1,000 | −3,000 | −11,000 | 16,000 | |
| Total other income (loss), net | 4 | 739,000 | −481,000 | −354,000 | −286,000 | |
| Net loss | −38 | −22 | −20 | −18 | −14 | |
| Unrealized foreign currency translation gain (loss) | 53,000 | −62,000 | 415,000 | 210,000 | 498,000 | |
| Total other comprehensive income (loss) | 53,000 | −62,000 | 415,000 | 210,000 | 498,000 | |
| Total comprehensive loss | −38 | −22 | −19 | −18 | −13 | |
| Deemed dividends | 0 | −619,000 | 0 | — | — | |
| Net loss attributable to common shareholders | −38 | −22 | −20 | — | — | |
| Net loss per share: basic | −1.05 | −1.22 | −14.12 | −37.88 | −3.23 | |
| Net loss per share: diluted | −1.05 | −1.22 | −14.12 | −37.88 | −3.23 | |
| Weighted average number of shares outstanding: basic | 36 | 18 | 1 | 480,688 | 4 | |
| Weighted average number of shares outstanding: diluted | 36 | 18 | 1 | 480,688 | 4 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2024 2024-03-31 | FY 2023 2023-12-31 | FY 2023 2023-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 98 | 51 | — | — | — | |
| Restricted cash | 113,000 | 63,000 | — | — | — | |
| Trade and other receivables | 33,000 | 229,000 | — | — | — | |
| Prepaid and other assets | 628,000 | 516,000 | — | — | — | |
| Total current assets | 99 | 52 | — | — | — | |
| Property and equipment, net | 131,000 | 179,000 | — | — | — | |
| Deposits | 55,000 | 25,000 | — | — | — | |
| Prepaid and other assets | 28,000 | 62,000 | — | — | — | |
| Right-of-use assets | 860,000 | 270,000 | — | — | — | |
| Total assets | 100 | 52 | — | — | — | |
| Trade and other payables | 1 | 4 | — | — | — | |
| Accrued employee benefits | 426,000 | 475,000 | — | — | — | |
| Lease liabilities, current portion | 354,000 | 284,000 | — | — | — | |
| Total current liabilities | 2 | 5 | — | — | — | |
| Non-current accrued employee benefits | 0 | 38,000 | — | — | — | |
| Lease liabilities, less current portion | 495,000 | 0 | — | — | — | |
| Total liabilities | 2 | 5 | — | — | — | |
| Preferred stock, $0.0001 par value5,000,000 shares authorized; no shares issued and outstanding at June 30, 2025 and 2024, respectively | 0 | 0 | — | — | — | |
| Common stock, $0.0001 par value160,000,000 shares authorized; 26,250,469 shares and 10,086,119 shares issued and outstanding at June 30, 2025 and 2024, respectively | 2,000 | 1,000 | — | — | — | |
| Additional paid-in capital | 326 | 238 | 198 | 198 | 198 | |
| Accumulated deficit | −228 | −190 | −186 | −181 | −174 | |
| Accumulated other comprehensive loss | −839,000 | −892,000 | — | — | — | |
| Total stockholders' equity | 97 | 47 | — | — | — | |
| Total liabilities and stockholders' equity | 100 | 52 | — | — | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 66,000 | 87,000 | 136,000 | 167,000 | 231,000 | |
| Amortization of right-of-use assets | 330,000 | 256,000 | 245,000 | 225,000 | 193,000 | |
| Share-based compensation expense | 17 | 830,000 | 452,000 | 870,000 | 634,000 | |
| Trade and other receivables | 197,000 | −176,000 | −50,000 | 1,000 | 28,000 | |
| Prepaid and other assets | −111,000 | 645,000 | −414,000 | 62,000 | −4,000 | |
| Trade and other payables | −2 | 941,000 | 1 | 1 | 55,000 | |
| Accrued employee benefits | −81,000 | 39,000 | 73,000 | 80,000 | 121,000 | |
| Lease liabilities | −356,000 | −275,000 | −252,000 | −196,000 | −192,000 | |
| Net cash used in operating activities | −24 | −19 | −18 | −16 | −13 | |
| Purchase of property and equipment | −18,000 | −179,000 | −1,000 | −13,000 | −221,000 | |
| Net cash used in investing activities | −18,000 | −179,000 | −1,000 | −13,000 | −221,000 | |
| Proceeds from issuance of common stock, pre-funded warrants, and common warrants | 30 | 71 | 18 | — | — | |
| Proceeds from exercise of pre-funded warrants, Series 2 warrants common warrants | 42 | 3 | — | — | — | |
| Share and pre-funded warrants issuance transaction costs | −2 | −6 | −2 | — | — | |
| Net cash provided by financing activities | 70 | 68 | 16 | — | 23 | |
| Effects of exchange rate changes on cash, cash equivalents, and restricted cash | 49,000 | −8,000 | 412,000 | 204,000 | 499,000 | |
| Net increase in cash, cash equivalents, and restricted cash | 47 | 48 | −2 | −16 | 10 | |
| Initial measurement of operating lease right-of-use assets and liabilities | 255,000 | 0 | — | — | — | |
| Re-measurement of operating lease right-of-use assets and liabilities | 666,000 | 0 | — | — | — | |
| Deemed dividend | 0 | 619,000 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Benitec Biopharma Inc.'s CIK number?
Benitec Biopharma Inc.'s SEC CIK number is 0001808898 (1808898). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Benitec Biopharma Inc.'s SEC filings?
All of Benitec Biopharma Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Benitec Biopharma Inc. last report earnings?
Benitec Biopharma Inc. (BNTC) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-222879). This is Benitec Biopharma Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Benitec Biopharma Inc.'s most recent earnings 8-K?
Benitec Biopharma Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001193125-26-222879. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Benitec Biopharma Inc.'s latest earnings 8-K →
Look up any company's CIK number →